TIDMRENE

RNS Number : 8348X

ReNeuron Group plc

01 September 2022

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review

and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

 
 Name:                               ReNeuron Group plc 
 Name of Scheme:                     ReNeuron Share Option Schemes 
                                    --------------------------------------- 
 Period of Return:                   From 1 March 2022 to 31 August 2022 
                                    --------------------------------------- 
 Balance of unallotted securities    3,455,769 Ordinary Shares (of 1p each) 
  under scheme(s) from previous 
  return: 
                                    --------------------------------------- 
 Plus : The amount by which          - 
  the block scheme(s) has been 
  increased since the date 
  of the last Review (if any 
  increase has been applied 
  for): 
                                    --------------------------------------- 
 Less : Number of securities 
  issued/allotted under scheme(s) 
  during period                      82,270 
                                    --------------------------------------- 
 Equals : Balance under scheme(s)    3,373,499 Ordinary Shares 
  not yet issued/allotted at 
  end of period: 
                                    --------------------------------------- 
 Number and class of securities      20,000 ordinary shares on 13 May 2010 
  originally admitted and the 
  date of admission: 
                                    ---------------------------------------

Total Voting Rights

At 31 August 2022, the Company had 57,145,893 Ordinary Shares in issue, each carrying one voting right.

As the Company holds no ordinary shares in treasury, the figure of 57,145,893 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

ENDS

Contacts:

 
 ReNeuron                                                                www.reneuron.com/investors 
 Iain Ross, Chairman                                                                Via Walbrook PR 
 Catherine Isted, Chief Financial Officer 
 
 Liberum Capital Limited (NOMAD and Joint Broker) 
  Phil Walker (Investment Banking) 
  Richard Lindley (Investment Banking) 
  Ben Cryer (Investment Banking)                                                +44 (0)20 3110 2000 
 
 Allenby Capital Limited (Joint Broker)                                         +44 (0)20 3328 5656 
 James Reeve/George Payne (Corporate Finance) 
 Stefano Aquilino (Sales & Corporate Broking) 
 
 Walbrook PR (Media & Investor Relations)            +44 (0)20 7933 8780 or reneuron@walbrookpr.com 
 Paul McManus/Alice Woodings                              +44 (0)7980 541 893 / +44 (0)7407 804 654

About ReNeuron

ReNeuron is a UK based leader in proprietary stem cell derived exosome technologies, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary exosome technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

The Group has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-license both of these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRBKDBQABKDBFN

(END) Dow Jones Newswires

September 01, 2022 02:00 ET (06:00 GMT)

Reneuron (AQSE:RENE.GB)
Gráfica de Acción Histórica
De May 2024 a Jun 2024 Haga Click aquí para más Gráficas Reneuron.
Reneuron (AQSE:RENE.GB)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024 Haga Click aquí para más Gráficas Reneuron.